Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

8 days required by the inclusion criteria.

A total of 87 percent of patients in the placebo group completed treatment, as did 82 percent, 77 percent, and 62 percent in the 200, 400, and 600 mg/day Vimpat(R) groups.

Summary of Vimpat(R) Data Presented at 2008 AES Annual Meeting

Early Onset of Efficacy in the Initial Weeks of Treatment with Lacosamide: A Pooled Analysis of Three Phase II/III Trials

This analysis found that Vimpat(R) demonstrated statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day.

-- At the end of the first week of treatment in this study, when all participants in the active treatment groups were receiving 100 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (33.0 percent Vimpat(R) group vs. 19.4 percent placebo; p<.01). Also during the first week, 39.1 percent of patients treated with Vimpat(R) experienced a 50 percent or greater reduction in seizures, compared with 31.3 percent in the placebo group (p<.01).

-- By the end of the second week of treatment, when all participants in the treatment groups were receiving 200 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 percent placebo; p<.01). The percentage of patients with a 50 percent or greater reduction in seizure frequency was 40.2% for patients receiving Vimpat(R) and 32.2 percent for placebo (p<.01 vs. placebo).

-- These significant seizure reductions appeared to be maintained over subsequent weeks of Vimpat(R) treatment.


    Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.256)
    Michael Sperling, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty,
     PhD
    Thomas Jefferson Universit
'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider of ... today announced its participation in the 2014 Big Data ... solutions provide semantic linkage and meaning to Big Data ... manage diverse data. Ben Szekely, vice president and founding ... “life sciences data lake” and an approach for collecting ...
(Date:10/1/2014)... Greifensee, Switzerland (PRWEB) October 01, 2014 ... influence the quality of the final product. However, ... most regulated, regulatory frameworks such as Good Manufacturing ... is the responsibility of the manufacturer to interpret ... ensure consistent weighing performance quality. METTLER TOLEDO experts ...
(Date:10/1/2014)... 30, 2014 The participants committed to ... to spending their own time adjusting, tweaking and testing ... designs were ready for judging. , “I enjoyed being ... thought leader. “The entries showed a commendable range ... characteristics of the print medium and the creativity of ...
(Date:10/1/2014)... Award winning unified communications (UC) ... new-hosted collaboration bundles that combine next generation communication ... experiences for low, flat rate fees. With ... have optimized solutions to meet their technology needs. ... only minutes (1K, 5K, 10K increments) or audio ...
Breaking Biology Technology:Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2SoundConnect Launches New Audio, Web and Video Bundles 2
... Oct. 16 Compendia Bioscience, Inc.,today announced ... Premium Edition, a high-value product extension of ... Oncomine Research,Premium Edition includes custom gene filters, ... support for Oncomine Concepts Map,including the ability ...
... DRRX ) announced today that it will be hosting ... at 12:00 p.m. Eastern Time. A live audio,webcast of ... and will,be available by accessing DURECT,s homepage at ... to participate during the,live webcast, the call will be ...
... will receive milestones and ... by Altair - Altair to conduct clinical development ... FRANCISCO, Oct. 16 ,Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc., a new venture,capital-funded biotechnology company, has been created to ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 3Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 4Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 5
(Date:10/2/2014)... 2014 CARTES ... identification and mobility which is being held at ... 6 November 2014, is proud to announce the ... agency FABERNOVEL.        (Logo: http://photos.prnewswire.com/prnh/20140526/689195) ... to support innovative businesses from the digital security ...
(Date:10/2/2014)... 2014 CARTES SECURE CONNEXIONS 2014 Conference: ... Sector CARTES SECURE CONNEXIONS 2014 is being held ... 6 November 2014. This 29 th  international meeting for ... mobility, will bring together the global community of a ... programme of conferences will set the pace for the ...
(Date:10/1/2014)... inheritance, showing for the first time that offspring can ... at least., This confronting idea, known as telegony, dates ... the early 20th Century with the advent of genetics., ... Crean, Professor Russell Bonduriansky and Dr Anna Kopps manipulated ... They found that the size of the young was ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4Semen secrets: How a previous sexual partner can influence another male's offspring 2
... multiple languages, cultures, races and religions, but among this diversity ... more united through our ears. In fact Mihailo Antovic, ... proposes that our musical conceptualization brings together a world of ... of distinct ethnic backgrounds and languages in his home of ...
... registration and abstract submission is now open at ... to be held in the Middle-East and Africa region. ... part of a new series of ,IOF Regionals, around ... energize research efforts in the region while offering advanced ...
... A drug already approved for people with cancer ... form of dementia, UT Southwestern Medical Center researchers report. ... a first-generation drug for the prevention and treatment of ... for which there is no treatment," said Dr. Joachim ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Cancer drug holds promise as first treatment for common, inherited dementia 2